BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 7636496)

  • 1. Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C.
    Orito E; Mizokami M; Suzuki K; Ohba K; Ohno T; Mori M; Hayashi K; Kato K; Iino S; Lau JY
    J Med Virol; 1995 Jun; 46(2):109-15. PubMed ID: 7636496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotype, serum level of hepatitis C virus RNA and liver histology as predictors of response to interferon-alpha 2a therapy in Japanese patients with chronic hepatitis C.
    Mizokami M; Orito E; Gibo Y; Suzuki K; Ohba K; Ohno T; Lau JY
    Liver; 1996 Feb; 16(1):23-7. PubMed ID: 8868074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term responders without eradication of hepatitis C virus after interferon therapy: characterization of clinical profiles and incidence of hepatocellular carcinoma.
    Yabuuchi I; Imai Y; Kawata S; Tamura S; Noda S; Inada M; Maeda Y; Shirai Y; Fukuzaki T; Kaji I; Ishikawa H; Matsuda Y; Nishikawa M; Seki K; Matsuzawa Y
    Liver; 2000 Jul; 20(4):290-5. PubMed ID: 10959807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C.
    Kakumu S; Aiyama T; Okumura A; Iwata K; Ishikawa T; Yoshioka K
    J Gastroenterol Hepatol; 1997 Jun; 12(6):468-72. PubMed ID: 9195406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-alpha therapy for individuals with normal serum alanine aminotransferase levels before treatment.
    Orito E; Mizokami M; Suzuki K; Ohba KI; Ohno T; Mizuno M; Iijima Y; Saito H; Nemoto A; Nukuta N
    J Gastroenterol Hepatol; 1997 Jan; 12(1):58-61. PubMed ID: 9076625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon-alpha therapy in Japanese patients with chronic hepatitis C.
    Orito E; Mizokami M; Nakano T; Terashima H; Nojiri O; Sakakibara K; Mizuno M; Ogino M; Nakamura M; Matsumoto Y
    J Med Virol; 1994 Dec; 44(4):410-4. PubMed ID: 7897373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C.
    Karino Y; Toyota J; Sugawara M; Higashino K; Sato T; Ohmura T; Suga T; Okuuchi Y; Matsushima T
    Am J Gastroenterol; 1997 Jan; 92(1):61-5. PubMed ID: 8995939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial density analysis of hepatitis C virus particle populations in chronic hepatitis C patients treated with interferon-alpha.
    Kanto T; Hayashi N; Takehara T; Hagiwara H; Mita E; Oshita M; Katayama K; Kasahara A; Fusamoto H; Kamada T
    J Med Virol; 1995 Jul; 46(3):230-7. PubMed ID: 7561795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers.
    Blatt LM; Tong MJ; McHutchison JG; Russell J; Schmid P; Conrad A
    J Interferon Cytokine Res; 1998 Feb; 18(2):75-80. PubMed ID: 9506457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of serum levels of HCV RNA in early phase of IFN therapy; as a predictive marker of subsequent response.
    Yamakawa Y; Sata M; Suzuki H; Tanaka K; Tanaka E; Noguchi S; Ono K; Tanikawa K
    Hepatogastroenterology; 1998; 45(19):133-6. PubMed ID: 9496502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of thrice weekly vs daily human leucocyte interferon-alpha therapy for chronic hepatitis C. TVVH Study Group.
    Chemello L; Cavalletto L; Bernardinello E; Boccato S; Casarin P; Cavinato F; Urban F; Pontisso P; Cecchetto A; Gatta A; Alberti A
    J Viral Hepat; 1999 Jul; 6(4):321-7. PubMed ID: 10607247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment.
    Campistol JM; Esforzado N; Martínez J; Roselló L; Veciana L; Modol J; Casellas J; Pons M; de Las Cuevas X; Piera J; Oliva JA; Costa J; Barrera JM; Bruguera M
    Nephrol Dial Transplant; 1999 Nov; 14(11):2704-9. PubMed ID: 10534516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison.
    Tong MJ; Blatt LM; McHutchison JG; Co RL; Conrad A
    Hepatology; 1997 Dec; 26(6):1640-5. PubMed ID: 9398010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of early measurement of serum hepatitis C virus RNA in predicting response to interferon therapy in patients with chronic hepatitis C.
    Toyoda H; Kumada T; Nakano S; Takeda I; Sugiyama K; Kiriyama S; Sone Y; Miyata A
    Eur J Gastroenterol Hepatol; 1997 Mar; 9(3):245-9. PubMed ID: 9096424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group.
    Chemello L; Cavalletto L; Casarin C; Bonetti P; Bernardinello E; Pontisso P; Donada C; Belussi F; Martinelli S; Alberti A
    Ann Intern Med; 1996 Jun; 124(12):1058-60. PubMed ID: 8633819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short and long-term effects of interferon on serum markers of hepatitis C virus replication.
    Yatsuhashi H; Inoue O; Inokuchi K; Koga M; Nagataki S; Cha TA; Irvine B; Stempien M; Kolberg J; Urdea MS
    J Gastroenterol Hepatol; 1993; 8(1):1-6. PubMed ID: 8382537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon alpha 2a therapy.
    Suzuki T; Tanaka E; Matsumoto A; Urushihara A; Sodeyama T
    J Med Virol; 1995 Jun; 46(2):162-8. PubMed ID: 7636506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa.
    Zeuzem S; Lee JH; Franke A; Rüster B; Prümmer O; Herrmann G; Roth WK
    Hepatology; 1998 Apr; 27(4):1149-56. PubMed ID: 9537457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus genotypes 1 and 2 respond to interferon-alpha with different virologic kinetics.
    Kohara M; Tanaka T; Tsukiyama-Kohara K; Tanaka S; Mizokami M; Lau JY; Hattori N
    J Infect Dis; 1995 Oct; 172(4):934-8. PubMed ID: 7561212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.